Intelligence Login
Inventor Portal
  • Why PatentVest?
  • Our Solution
  • Case Studies
  • About
    • About Us
    • Our Team
    • Our Track Record
  • News & Media
    • Reports
    • Videos
    • Articles
    • Legal Articles
    • Press Releases
  • Contact Us
  • Inventor Portal
  • Intelligence Login
Contact
From Patent Risk to Strategic Clarity: How Docana Built an IP Strategy with PatentVest

From Patent Risk to Strategic Clarity: How Docana Built an IP Strategy with PatentVest

by Staff | Apr 22, 2026 | Case Studies

Case Study From Patent Risk to Strategic Clarity: How Docana Built an IP Strategy with PatentVest How an AI startup navigated the patent landscape, identified freedom to operate, and built a strategy to protect its innovation. Company: Docana Industry: Artificial...
Brain-Computer Interface: Who’s Leading, What They Own, and How IP Will Decide the Future

Brain-Computer Interface: Who’s Leading, What They Own, and How IP Will Decide the Future

by Staff | Mar 31, 2025 | PatentVest Pulse

Authors: Tyler Teske, Will Rosellini, Oscar Chow Highlights $400B+ Market, But Not for Everyone: The U.S. brain-computer interface (BCI) market is real—and enormous. But most of that value will be captured by a small number of companies that move early to secure...
AI-Driven Data Centers – The Patent Race Reshaping AI Infrastructure

AI-Driven Data Centers – The Patent Race Reshaping AI Infrastructure

by Staff | Mar 5, 2025 | PatentVest Pulse

Authors: Will Rosellini, Maria Ramos, Oscar Chow 1.0 Summary Data centers have evolved from infrastructure providers to become critical enablers, reflecting the changing landscape of generative AI. The increasing need for computational resources and optimized AI...

Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

by Staff | Feb 10, 2025 | Press Releases

Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025. Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) — Today, Invizyne Technologies, Inc., (NASDAQ: IZTC) (“Invizyne”), a leading designer of cell-free, enzyme-based biomanufacturing...

HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

by Staff | Jan 29, 2025 | Press Releases

SANTA CLARA, Calif.–(BUSINESS WIRE)– HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application to the U.S. Food and...
« Older Entries

Recent Posts

  • The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity
  • The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market.
  • From Patent Risk to Strategic Clarity: How Docana Built an IP Strategy with PatentVest
  • Using AI In Your Inventive Process? Proceed to Patent, But Carefully
  • The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine

Recent Comments

    Archives

    • June 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • October 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • February 2024
    • January 2024
    • November 2023
    • October 2023
    • June 2023
    • May 2023
    • November 2022
    • October 2022
    • August 2022
    • July 2022
    • June 2022

    Categories

    • Case Studies
    • Legal Reports
    • PatentVest Pulse
    • Press Releases
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Why PatentVest?Our SolutionAboutNews & Media

    Terms of Use  |       © 2026 – PatentVest, Inc.

    • Follow